Download PDF
Thromb Haemost 2014; 111(06): 1007-1008
DOI: 10.1160/TH14-03-0213
Invited Editorial Focus
Schattauer GmbH

Discontinuing clopidogrel: Abrupt or tapered cessation?

Peter L. Thompson
1   Heart Research Institute, Sir Charles Gairdner Hospital, University of Western Australia, Perth, Western Australia, Australia
› Author Affiliations
Further Information

Publication History

Received: 12 March 2014

Accepted after minor revision: 12 March 2014

Publication Date:
21 November 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 http://www.medscape.com/viewarticle/758119#1 ‘Irrational’ Choices Stall Adoption of New Antiplatelets Reed Miller Medscape Medical News February 06, 2012 from Cardiovascular Research Technologies (CRT) 2012. Last accessed March 1st 2014
    PubMed
  • 2 Kastrati A, Byrne RA, Schulz S. Will we ever know the optimal duration of dual antiplatelet therapy after drug-eluting stent implantation?. JACC Cardiovasc Interv 2011; 04: 1129-1132.
    CrossrefPubMedSearch in Google Scholar
  • 3 Mauri L, Kereiakes DJ, Normand SL. et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am Heart J 2010; 160: 1035-1041.
    CrossrefPubMedSearch in Google Scholar
  • 4 Byrne RA, Schulz S, Mehilli J. et al. Intracoronary Stenting, Antithrombotic Regimen: Safety And EFficacy of Six Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) Investigators. Rationale and design of a randomized, double-blind, placebo-controlled trial of 6 versus 12 months clopidogrel therapy after implantation of a drug-eluting stent: The Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) study. Am Heart J 2009; 157: 620-624.
    CrossrefPubMedSearch in Google Scholar
  • 5 Levine GN, Bates ER, Blankenship JC. et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation 2011; 124: 2574-2609.
    CrossrefPubMedSearch in Google Scholar
  • 6 Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC), the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI). Wijns W, Kolh P, Danchin N. et al. Guidelines on myocardial revascularization. Eur Heart J. 2010 31. 2501-2555.
    PubMedSearch in Google Scholar
  • 7 Mehran R, Baber U, Steg PG. et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 2013; 382: 1714-1722.
    CrossrefPubMedSearch in Google Scholar
  • 8 Diehl P, Halscheid C, Olivier C. et al. Discontinuation of long term clopidogrel therapy induces platelet rebound hyperaggregability between 2 and 6 weeks post cessation. Clin Res Cardiol 2011; 100: 765-771.
    CrossrefPubMedSearch in Google Scholar
  • 9 Ho PM, Peterson ED, Wang L. et al. Incidence of death and acute myocardial infarction associated with stopping clopidogrel after acute coronary syndrome. J Am Med Assoc 2008; 299: 532-539.
    CrossrefPubMedSearch in Google Scholar
  • 10 Fiedler KA, Mehilli J, Kufner S. et al. Randomized, Double-Blind Trial on the Value of Tapered Discontinuation of Clopidogrel Maintenance Therapy after Drug-Eluting Stent Implantation. Intracoronary Stenting and Antithrombotic Regimen: CAUTION in Discontinuing Clopidogrel Therapy - ISAR-CAUTION. Thromb Haemost 2014; 111: 1041-1049.
    Thieme ConnectPubMedSearch in Google Scholar
  • 11 Garg S, Bourantas C, Serruys PW. New concepts in the design of drug-eluting coronary stents. Nat Rev Cardiol 2013; 10: 248-260.
    CrossrefPubMedSearch in Google Scholar
  • 12 Price MJ, Berger PB, Teirstein PS. et al. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomized trial. J Am Med Assoc 2011; 305: 1097-1105.
    CrossrefPubMedSearch in Google Scholar
  • 13 Quote Investigator. Exploring the origin of quotations It’s Difficult to Make Predictions, Especially About the Future. http://quoteinvestigator.com/2013/10/20/no-predict/ Accessed March 1, 2014
    PubMed